Japan’s JCR Pharmaceuticals (TYO: 4552) has reached an agreement to acquire ArmaGen, a privately held US biopharmaceutical company, along with all its assets.
On completing the transaction in late April, ArmaGen will become a wholly-owned subsidiary of JCR.
JCR is currently focused on the research and development of innovative drugs for lysosomal storage disorders (LSDs) on the platform of its unique blood-brain barrier (BBB) penetration technology, J-Brain Cargo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze